From: Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
Trial | ClinicalTrials.gov identifier |
---|---|
Biologics | Â |
Bevacizumab in combination with crossover fluoropyrimidine-based chemotherapy beyond progression (stratum 1: AIO-IRI, FOLFIRI, CAPIRI or XELIRI; stratum 2: FUFOX, FOLFOX, CAPOX or XELOX) (ML 18147 study)* | NCT00700102 |
Aflibercept plus irinotecan and 5-FU following failure of an oxaliplatin-based regimen (VELOUR) | NCT00561470 |
Ramucirumab plus FOLFIRI following progression with first-line bevacizumab, oxaliplatin, and fluoropyrimidine | NCT01183780 |
TKIs | Â |
Brivanib alaninate in combination with the EGFR monoclonal antibody cetuximab following previous chemotherapy | NCT00640471 |
Cediranib plus chemotherapy (FOLFOX or XELOX) as first-line treatment (HORIZON II) | NCT00399035 |
Cediranib plus FOLFOX vs bevacizumab plus FOLFOX as first-line treatment (HORIZON III) | NCT00384176 |
Regorafenib plus best supportive care following failure of standard therapies (CORRECT) | NCT01103323 |
Sunitinib plus FOLFIRI as first-line treatment | NCT00457691 |
Vatalanib plus oxaliplatin/5-FU/leucovorin following previous treatment with irinotecan | NCT00056446 |